Results 281 to 290 of about 185,606 (358)

Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

open access: yesMovement Disorders, EarlyView.
Abstract Background The first International Parkinson and Movement Disorder Society Evidence‐Based Medicine (MDS‐EBM) review for essential tremor (ET) was published in 2019; since then, the modified Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was adopted by MDS, and new evidence exists.
Deepa Dash   +12 more
wiley   +1 more source

Serum Vitamin D Level and Clinical Risk Factors for Benign Paroxysmal Positional Vertigo. [PDF]

open access: yesCureus
Nava-Gaytán CA   +3 more
europepmc   +1 more source

Clinical, Genetic, and Imaging Characteristics of SCA27B: Insights from a Large Dutch Cohort

open access: yesMovement Disorders, EarlyView.
Abstract Background Deep intronic GAA repeat expansions in intron 1 of the FGF14 gene were identified in 2023 as cause of late‐onset cerebellar ataxia. Since then, GAA‐FGF14‐related ataxia (SCA27B) has emerged as one of the most common genetic causes of late‐onset cerebellar ataxia.
Teije H. van Prooije   +26 more
wiley   +1 more source

Diagnostic utility of smartphone-integrated gait analysis in the assessment of BPPV. [PDF]

open access: yesFront Neurol
Durmus K   +6 more
europepmc   +1 more source

Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review

open access: yesMedicine Advances, EarlyView.
Research shows that (R, S)‐ketamine and its stereoisomers effectively reduce symptoms of post‐traumatic stress disorder (PTSD) and treatment‐resistant depression, with (R)‐ketamine offering similar benefits with fewer side effects. Evidence highlights specific neural circuits and regions, including the dentate gyrus, prefrontal cortex, vCA3, dorsal ...
Thomas Edward Cutting   +1 more
wiley   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy